{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:03:30Z","timestamp":1761959010887,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.012","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T04:51:45Z","timestamp":1270011105000},"page":"S8-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Enhancing Existing Approaches to Peripheral T-Cell Lymphoma"],"prefix":"10.1053","volume":"47","author":[{"given":"Francine M.","family":"Foss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.012_bib1","doi-asserted-by":"crossref","first-page":"1011a","DOI":"10.1182\/blood.V110.11.3452.3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstr 3452]","volume":"110","author":"Abouyabis","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib3","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib4","first-page":"v131","article-title":"ESHAP chemotherapy regimen and 13-cis-retinoic acid in elderly patients with untreated poor-prognosis peripheral T cell lymphoma: a GELA phase II trial of feasibility and efficacy [abstr 322]","volume":"16","author":"Bouabdallah","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1445-5994.2007.01397.x","article-title":"Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim","volume":"37","author":"Spencer","year":"2007","journal-title":"Intern Med J"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","article-title":"CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas","volume":"58","author":"Kim","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib8","doi-asserted-by":"crossref","first-page":"447s","DOI":"10.1200\/jco.2009.27.15_suppl.8554","article-title":"A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial [abstr 8553]","volume":"27","author":"Delmer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib10","doi-asserted-by":"crossref","first-page":"268b","DOI":"10.1182\/blood.V108.11.4740.4740","article-title":"Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma [abstr 4740]","volume":"108","author":"Intragumtornchai","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib11","doi-asserted-by":"crossref","first-page":"1011a","DOI":"10.1182\/blood.V110.11.3449.3449","article-title":"Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial [abstr 3449]","volume":"110","author":"Foss","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/10428190600562823","article-title":"First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +\/\u2212 radiotherapy is active in stage I\/II extranodal NK\/T-cell lymphoma","volume":"47","author":"Lee","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V114.22.2689.2689","article-title":"Long-term outcomes of patients with newly diagnosed NK\/T-cell lymphoma treated by EPOCH regimen [abstr 2689]","volume":"114","author":"Huang","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V112.11.579.579","article-title":"A prospective phase II trial of an L-asparaginase containing regimen in patients with refractory or relapsing extra nodal NK\/T-cell lymphoma [abstr 579]","volume":"112","author":"Jaccard","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib17","doi-asserted-by":"crossref","first-page":"258a","DOI":"10.1182\/blood.V104.11.904.904","article-title":"Autologous stem cell transplanation as first line therapy in peripheral T cell lymphomas","volume":"104","author":"Reimer","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.012_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood.V114.22.1660.1660","article-title":"Aggressive primary chemotherapy plus autologous stem cell transplantation improves outcome for peripheral T cell lymphomas compared with CHOP-like regimens [abstr 1660]","volume":"114","author":"Sieniawski","year":"2009","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:12Z","timestamp":1758522012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":18,"alternative-id":["S0037196310000132"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.012","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing Existing Approaches to Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}